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Abstract
Shed cells or disrupted parts of the biofilm may enter the circulation causing serious and very hard
to treat biofilm-associated infections. The activity of antimicrobial agents against the shed cells/
disrupted biofilms is largely unknown.
Methods: We studied the in vitro susceptibility of intact and disrupted biofilms of thirty clinical
isolates of methicillin-resistant and methicillin–susceptible Staphylococcus aureus (MRSA and MSSA)
and Staphylococcus epidermidis to vancomycin, quinupristin/dalfopristin, and linezolid and compared
it to that of the suspended (planktonic) cells.
Results: Bacteria in the disrupted biofilms were as resistant as those in the intact biofilms at the
minimum inhibitory concentrations of the antibiotics. At higher concentrations, bacteria in the
disrupted biofilms were significantly (P < 0.001) less resistant than those in the intact biofilms but
more resistant than the planktonic cells. Quinupristin/dalfopristin showed the best activity against
cells of the disrupted biofilms at concentrations above MICs and vancomycin, at 500 and 1,000 µg/
ml, was significantly more active against the biofilms of MRSA and S. epidermidis
Conclusion: The difficulty of treating biofilm-associated infections may be attributed not only to
the difficulty of eradicating the biofilm focus but also to the lack of susceptibility of cells disrupted
from the biofilm to antimicrobial agents.
Introduction
Gram-positive infections have become a serious problem,
especially in the nosocomialsetting, and treatment of
these infections is complicated by the emergence of multi-
drug-resistant pathogens [1]. Infections caused by Staphy-
lococcus aureus and Staphylococcus epidermidis are among
the most frequent causes of both healthcare-associated
and community-onset infections [2]. Staphylococci cause
a large percentage of infections by forming biofilms on
medical implants, damaged tissues, and most commonly
on indwelling vascular catheters [3-7].
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Biofilm-associated infections are becoming more com-
mon, and occur largely because of the increase in the use
of indwelling medical devices. Central venous catheters
(CVCs), for example, are inserted in more than 20 million
hospitalized patients in the United States alone each year
[8]. The mortality rate due to CVC-related bloodstream
infections is estimated to be 12–25%, with additional
healthcare costs in the order of $33,000 to $35,000 per
event [9]. The predominant microorganisms associated
with CVC-related infections are Staphylococcus epidermidis
and Staphylococcus aureus where they are often found in
biofilms upon removal of the devices [10-12]. Biofilm
associated infections are difficult to treat due to the inher-
ent antibiotic resistance of the sessile bacteria [4,6,13]. A
number of factors contribute to this resistance such as a
slow growth rate [14,15], failure of the agent to penetrate
the biofilm [16,17], physiological changes and gene
expression or repression due to the biofilm mode of
growth [18,19]. Other factors such as age of the biofilms
[20], production of extracellular polymeric substance
(EPS) [21-23], and presence of biomaterials [24] also play
a role in decreasing susceptibility of the bacteria within
the biofilms to antimicrobial agents.
Routinely, the diagnostic laboratories report the suscepti-
bilities done on planktonic bacteria only. Although many
studies have focused on the antimicrobial susceptibility of
bacteria grown in biofilms [25-28], none of these studies
included bacteria that disrupted from the biofilms. Dis-
ruption of the biofilm can occur during the removal of
colonized catheters or during fluid infusion through
them. The result is the entrance of bacteria or groups of
bacteria shed from the biofilm into circulation causing
bloodstream infections. These bacteria may not belong to
either the planktonic or the biofilm phase and conse-
quently may have a different pattern of antimicrobial sus-
ceptibility. For this reason, we studied the in vitro
susceptibility of intact and disrupted biofilms of MRSA,
MSSA and S. epidermidis to vancomycin, quinupristin/dal-
fopristin, and linezolid and compared it to the suscepti-
bility patterns of the same bacteria in suspension.
1. Materials and Methods
Unless otherwise indicated, all chemicals (analytical
grade) were purchased from Sigma Chemical Co., St.
Louis, Missouri, USA.
Antibiotics
Vancomycin (VAN) was purchased from Sigma Chemical
Co., St. Louis, Missouri, USA. Quinupristin/dalfopristin
(Q/D) was provided by Rhone-Poulenc Rorer, Colle-
geville, PA, USA and Linezolid (LNZ) was provided by
Pharmacia & Upjohn, Kalamazoo, MI, USA.
Microorganisms
Ten isolates each of MRSA, MSSA, and S. epidermidis were
used in this study. The microorganisms are clinical iso-
lates from patients with blood stream infections which
were provided by the microbiology laboratories at St.
John's Hospital, Springfield, Illinois. These isolates were
screened for biofilm formation on polystyrene microliter
plates as previously described [27].
Antimicrobial susceptibility in suspension
The minimum inhibitory concentrations (MICs) of the
antibiotics were determined by using the broth microdilu-
tion technique as described by the National Committee
for Clinical Laboratory Standards (NCCLS) [29]. The min-
imum bactericidal concentrations (MBCs) were deter-
mined by mixing the contents of each well at MIC and
higher concentrations. Ten-microliter portions were then
taken from each well and streaked onto the surface of
blood agar. After 24 h incubation, the number of colony
forming units per milliliter (CFU/ml) were counted and
the MBCs, defined as the concentration at which 99.9% of
bacteria was killed, were determined. The MIC90  and
MBC90 obtained in susceptibility testing on planktonic
bacteria were used in interpreting the results of the exper-
iments with intact and disrupted biofilms.
Biofilm formation and quantification
To form biofilms, 100 µl portions of Tryptic Soy Broth
(TSB) (Difco laboratories, Detroit, MI, USA) containing 1
× 106 CFU/ml of the microorganisms were delivered to
flat bottom 96 polystyrene plates (Falcon No. 353072,
Becton Dickinson and Company, Franklin Lakes, NJ,
USA). After 24 h incubation at 37°C, the supernatants
were aspirated and the remaining biofilms were washed
twice with distilled water. TSB with or without the antibi-
otics at MIC values or at 50,500, or 1,000 µg/ml was
added to the wells. Biofilms in the plates used for dis-
rupted wells were then dislodged by using sterile wooden
sticks and all plates were incubated again for 24 h. Plates
with disrupted biofilms were centrifuged at 3,000 rpm for
15 min. to sediment the biofilm particles and all plates
were then cautiously aspirated. The intact biofilms and
the sediments of the disrupted biofilms were then deter-
mined by using a modified colorimetric assay previously
described by Roslev & King [30]. On this assay, bacteria
with an active electron transport system reduce the tetra-
zolium salt (redoxdye) to water soluble orange formazan
product. Briefly, 100 µl lactate Ringers solution contain-
ing tetrazolium sodium 3'-{1- [(phenylamino)-carbonyl]-
3,4-tetrazolium}-bis (4-methoxy-6-nitro) benzene sul-
fonic acid hydrate (XTT) (0.5 gm/L) and menadione (1
µM) was added to the intact biofilms and the disrupted
biofilm sediments. The contents of the plates were mixed
via plate shaker (Lab-Line Instruments Inc., Melrose Park,
IL, USA) for 5 min followed by incubation for 1 hat 37°CAnnals of Clinical Microbiology and Antimicrobials 2005, 4:2 http://www.ann-clinmicrob.com/content/4/1/2
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in the dark. Plates with disrupted biofilm were first centri-
fuged for 15 min at 4°C, and the supernatants containing
the soluble colored formazon were transferred to new
plates. The intensity of the color was then measured via
micro plate reader (Multiscan Plus, Thermosan Systems,
Finland) at 490 nm and compared to that of drug-free
wells. For plates with intact biofilms, the intensity of the
color of the soluble formazan was measured directly and
compared to drug-free wells.
Confocal Scanning Laser Microscopy (CSLM)
One-milliliter portions of TSB containing 1 × 106 CFU/ml
of S. epidermidis isolate (SE6) were used to inoculate ster-
ile plastic cover slips placed in a 4 well multidish (Nunc
No. 176740, Roskilde, Denmark). After 24 h incubation
at 37°C, the cover slips were moved to new plates and
washed twice with distilled water. Fresh TSB (1 ml) with
500 µg/ml of vancomycin was added to the wells. Bio-
films on cover slips designed to study the disrupted bio-
films were then carefully dislodged. After incubation for
another 24 h, the biofilms (intact and disrupted) were
stained with LIVE/DEAD BacLight bacterial viability stain
(Molecular Probes, Eugene, OR, USA) following manufac-
turer's instructions. The biofilms (intact and disrupted)
were then examined by Olympus Fluoview CSLM (model
IX 70, Olympus America Inc. NY, USA).
In another set of experiments, the susceptibility of plank-
tonic cells was examined by growing the bacteria in 1 ml
portions of TSB. After 24 h, the bacterial suspensions were
centrifuged at 10,000 rpm for 10 minutes, washed twice
with sterile distilled water and finally dispersed in 1 ml
portions of fresh TSB with the antibiotic. After another 24
h of incubation, the bacteria were stained and examined
as previously mentioned.
Statistical Analysis
The mean and S.D. were calculated from the results of 10
isolates of each of the Staphylococcal species. One-way
analysis of variance (ANOVA) was used to determine the
differences between various antibiotic treatments. Tukey's
pair comparison test was used at the chosen level of prob-
ability (P  < 0.05) to determine significance difference
between means.
Results
In suspensions, all isolates were susceptible to all antibi-
otics tested (Table 1). At MICs, the antibiotics showed
very little effect on the viability of bacteria within the bio-
films (intact or disrupted). At higher concentrations
(50,500 and 1000 µg/ml), the biofilms of all isolates were
significantly (P < 0.001) less susceptible to the antibiotics
compared to disrupted biofilms (Figures 1, 2, 3). Line-
zolid was less active than quinupristin/dalfopristin and
vancomycin in killing the bacteria, especially in the
biofilms.
Quinupristin/dalfopristin showed the best activity against
cells of the disrupted biofilms at concentrations above
MICs. It was also more active than vancomycin against
biofilms of both S. aureus and S. epidermidis at 50 µg/ml.
Vancomycin at 500 and 1,000 µg/ml, was significantly
more active against the biofilms of MRSA and S. epider-
midis but not MSSA. Killing of the bacterial cells in intact
Table 1: Susceptibility of the tested isolates to vancomycin, quinupristin/dalfopristin and linezolid in suspension.
Microorganism a Antimicrobial agents (µg/ml)
Vancomycin Quinupristin/dalfopristin Linezolid
Methicillin-susceptible S. aureus (MSSA)
MIC Range 0.50–1 0.125–0.25 1–2
MIC90 10 . 2 52
MBC Range 8–16 8 >64
MBC90 88 > 6 4
Methicillin-resistant S. aureus (MRSA)
MIC Range 0.5–1 0.25–50 1–2
MIC90 10 . 5 02
MBC Range 2–16 4–16 >64
MBC90 81 6 > 6 4
S. epidermidis
MIC Range 2–4 0.06–2 0.50–1
MIC90 20 . 5 01
MBC Range 2–16 0.25–16 >64
MBC90 88 > 6 4
a The MIC defined as the minimum concentration of antibiotic at which growth was completely inhibited while the MBC defined as the minimum 
concentration at which 99.9% of bacteria was killed.Annals of Clinical Microbiology and Antimicrobials 2005, 4:2 http://www.ann-clinmicrob.com/content/4/1/2
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or disrupted biofilms by quinupristin/dalfopristin and
linezolid was independent of antibiotic concentrations
over the range of 50–1,000 µg/ml, but for vancomycin,
this was observed at higher concentration range (500–
1,000 µg/ml). The ratios of viability of disrupted biofilms
to that of intact biofilms were calculated for the isolates
with each antibiotic concentration (Figure 4). The ratio
values were similar for the three antibiotics at MICs. At
other concentrations, the highest viability ratio was
observed with linezolid and the lowest with quinupristin/
dalfopristin.
CSLM (Figure 5) demonstrated resistance of the intact
biofilms to vancomycin, indicated by large number of via-
ble cells, and resistance of the disrupted biofilm com-
pared to the planktonic cells. It is also clear that the
disrupted biofilm consists of clumps of larger size com-
pared to that of the planktonic cells.
Discussion
Coagulase-negative staphylococci and S. aureus (mostly
methicillin-resistant) are among the leading causes of
nosocomial blood stream infections in the USA [31] with
a crude mortality of 21–25% respectively [32]. S. aureus
accounted for up to 13% of isolates recovered from
patients with nosocomial infections from 1979 through
1995, and the percentage has increased in recent years
[33,34]. It has been estimated that 65% of nosocomial
infections are biofilm associated [5,35]. S. epidermidis is a
common cause of blood stream infections associated with
indwelling medical devices. S. aureus, in addition to caus-
Susceptibility of intact and disrupted biofilms of MSSA, MRSA, and S. epidermidis at different concentrations of vancomycin Figure 1
Susceptibility of intact and disrupted biofilms of MSSA, MRSA, and S. epidermidis at different concentrations of vancomycin.Annals of Clinical Microbiology and Antimicrobials 2005, 4:2 http://www.ann-clinmicrob.com/content/4/1/2
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ing blood stream infections, is a significant cause of tissue
infections such as pneumonia and osteomyelitis [5].
Three phases of bacteria were used in this study; plank-
tonic, biofilms and disrupted biofilms. Planktonic cells
were used for determination of MICs and MBCs. This
phase of bacteria has routinely been used as gold standard
for determination of susceptibility of bacteria and predic-
tion of clinical efficacy of antimicrobial agents. Planktonic
cells grown in in vitro batch cultures are usually in nutri-
ent-rich medium. Bacteria grown in biofilms differ greatly
from the same organisms grown in suspensions by having
different growth characteristics and taking up nutrients
and drugs differently [36,37]. When a biofilm is at steady
state, cells are shed from it at a constant rate [38]. These
cells may enter into circulation and cause blood stream
infection. Biofilm associated infections are 10 to 1,000
times more resistant to the effects of antimicrobial agents
[5,35,39]. Bacteria are shed through biofilm disruption,
which may result in entrance of biofilm pieces into
circulation causing systemic infections. The question that
needed to be answered is whether these cells behave as
planktonic cells or as biofilm in regards to susceptibility
to antimicrobial agents.
Susceptibility of intact and disrupted biofilms of MSSA, MRSA, and S. epidermidis at different concentrations of quinupristin/dal- fopristin Figure 2
Susceptibility of intact and disrupted biofilms of MSSA, MRSA, and S. epidermidis at different concentrations of quinupristin/dal-
fopristin.Annals of Clinical Microbiology and Antimicrobials 2005, 4:2 http://www.ann-clinmicrob.com/content/4/1/2
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We used 24 h incubation for interaction with antimicro-
bial agents in keeping with the procedures followed in
diagnostic laboratories. Although it is possible that during
this long incubation period the disrupted biofilm could
have re-adhered to the polystyrene, we believe this was
not the case. This is based on finding in our and other lab-
oratories that antimicrobial agents are able to prevent the
adherence of bacteria when exposed to them prior to for-
mation of the biofilm [25-27]
All isolates in suspension were susceptible to the antibiot-
ics as determined by NCCLS guidelines. Vancomycin and
quinupristin/dalfopristin were capable of killing 99.9 %
of the bacteria in suspension at concentrations up to 16
µg/ml, while linezolid, a bacteriostatic antibiotic, did not
show such effect even at the maximum concentration
used. At the MICs, the antibiotics exerted little effect on
the viability of the intact and disrupted biofilms. This was
expected because even in suspension the MIC90s were 4–
8 times lower then the MBC90s for vancomycin and 16–32
times lower for quinupristin/dalfopristin. At higher con-
centrations, although the intact biofilms were signifi-
cantly more resistant than the disrupted biofilms, the
recalcitrance of the latter was clear. The antibiotic concen-
Susceptibility of intact and disrupted biofilms of MSSA, MRSA, and S. epidermidis at different concentrations of linezolid Figure 3
Susceptibility of intact and disrupted biofilms of MSSA, MRSA, and S. epidermidis at different concentrations of linezolid.Annals of Clinical Microbiology and Antimicrobials 2005, 4:2 http://www.ann-clinmicrob.com/content/4/1/2
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trations were 100–4,000 times the MIC90s for quinupris-
tin/dalfopristin and 25–1,000 times the MIC90s for
vancomycin and linezolid. None of these concentrations
were able to kill 99.9 % of the microorganisms in the dis-
rupted phase. This was further demonstrated by examin-
ing the viability of S. epidermidis cells in the three phases
in the presence of vancomycin by using CSLM. The sus-
ceptibility of the disrupted biofilm lies between the highly
resistant biofilm and the susceptible planktonic cells. This
may be attributed to the fact that disrupted biofilms con-
sist of fragments that may retain some features of the
intact biofilms. It is obvious from the images that the dis-
rupted biofilm consists of large clumps and aggregates
compared to the typical clusters of planktonic cells. The
semi quantitative assessment of viability by CSLM was
similar to those obtained by the colorimetric assay.
Viability ratios of MSSA, MRSA, and S. epidermidis of disrupted to intact biofilms at different concentrations of vancomycin,  quinupristin/dalfopristin and linezolid Figure 4
Viability ratios of MSSA, MRSA, and S. epidermidis of disrupted to intact biofilms at different concentrations of vancomycin, 
quinupristin/dalfopristin and linezolid.Annals of Clinical Microbiology and Antimicrobials 2005, 4:2 http://www.ann-clinmicrob.com/content/4/1/2
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Killing of the bacterial cells in intact or disrupted biofilms
by quinupristin/dalfopristin and linezolid was
independent of antibiotic concentrations over the range
of 50–1000 µg/ml and over a higher range of vancomycin
concentrations (500–1,000 µg/ml). Hamilton-Miller &
Shah [40] found that killing of S. epidermidis in the bio-
film by quinupristin/dalfopristin was independent of
antibiotic concentrations over the range of 20–200 times
the MIC. This lack of dose response at high concentrations
favors the hypothesis that the bacteria disrupted from the
biofilm are more or less similar to those in the biofilm
rather than the bacteria in suspension.
For better comparison, the viability ratios of the disrupted
to the intact biofilms were calculated at different concen-
trations of the antibiotics. Linezolid was less efficient in
killing bacterial cells in intact or disrupted biofilms which
explains its highest viability ratio. Quinupristin/dalfopris-
tin, with the lowest viability ratio, was more active against
the cells of the disrupted biofilms at concentrations above
MICs for both S. aureus and S. epidermidis. It was also more
active than vancomycin against biofilms of both S. aureus
and S. epidermidis at 50 µg/ml. On the other hand, vanco-
mycin at 500 and 1,000 µg/ml, was significantly more
active against the biofilms of MRSA and S. epidermidis but
not MSSA. It has been reported that vancomycin accumu-
lates at high concentration in the biofilms of gram posi-
tive bacteria especially S. epidermidis compared to
linezolid [41]. This may be attributed to the ability of glyc-
opeptides to bind to exopolysaccharides produced by the
bacteria. However, such high concentrations of vancomy-
cin or quinupristin/dalfopristin are not achievable in clin-
ical practice.
In general, our data show that Quinupristin/dalfopristin
is more active than vancomycin and linezolid against the
disrupted biofilms and there was no difference between
methicillin-susceptible and methicillin resistant staphylo-
cocci. We conclude that the difficulty in treating the infec-
tions related to indwelling medical devices may not be
only due to lack of eradication of the cells in the biofilm
phase, but also due to resistance of bacteria disrupted
from the biofilm.
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CSLM images of S. epidermidis (SE6) intact biofilms (A), disrupted biofilm (B) and planktonic cells (C) on plastic coverslips after  incubation for 24 h with 500 µg/ml of vancomycin Figure 5
CSLM images of S. epidermidis (SE6) intact biofilms (A), disrupted biofilm (B) and planktonic cells (C) on plastic coverslips after 
incubation for 24 h with 500 µg/ml of vancomycin. The bacterial cells were stained with LIVE/DEAD BacLight bacterial viability 
stain to directly visualize the effects of the antibiotic. The green fluorescence reflects processing of the dye by metabolically 
active cells while the red fluorescence is characteristic of dead cells. Note that while the green fluorescence was considerably 
more prominent in the intact biofilm image, the disrupted biofilm does display more green fluorescence than the planktonic 
cells. Also, note that the disrupted biofilm consists of large clumps and aggregates compared to the typical clusters of plank-
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